Synchrony® Raises the Bar in AAPM MArkerless Lung Target Tracking Challenge (MATCH)

To watch the recorded MyAccuray webinar, please fill out the form
Delivering effective and safe lung cancer stereotactic body radiation therapy (SBRT) requires technology that can account for lung tumor motion. Request a demo to see firsthand how Synchrony achieves superior precision and accuracy in the treatment of moving targets.
MATCH Compares Markerless Tracking Technologies
Delivering effective and safe lung cancer stereotactic body radiation therapy (SBRT) requires technology that can account for lung tumor motion. Both fiducial-based and markerless tracking algorithms currently exist, with markerless being a focus of innovation, investment and research in the field. These tracking algorithms, however, have not been benchmarked using a common, prospective measurement methodology. The American Association of Physicists in Medicine (AAPM) designed the MArkerless Lung Target Tracking CHallenge (MATCH), an AAPM Grand Challenge, to compare the precision and accuracy of existing markerless tracking algorithms.
Synchrony Markerless Lung Tracking Provides Clinical Benefits such as Enhanced Precision and Accuracy
Accuray customers, using the Accuray Synchrony® Lung Tracking™ with Respiratory Modeling on the Radixact® System, the next-generation TomoTherapy® platform, and CyberKnife® System, achieved the highest levels of accuracy and precision, taking top honors in the AAPM MATCH challenge.
- Improved Clinical Confidence: Physicists can feel confident in accurate beam-delivery synchronization to moving targets.
- Increased Precision: Clinicians can deliver radiation with submillimeter accuracy, significantly reducing margins and minimizing irradiation of healthy tissues and critical structures.
- Greater Patient Comfort: Patients can breathe normally, without uncomfortable restraints, or difficult and inefficient gating techniques.
- Non-Invasive Option: Markerless tracking provides a truly non-invasive treatment option for medically inoperable patients.